Prestige Consumer Healthcare Inc. 8-K

What Happened

• On May 10, 2026, Prestige’s Australian subsidiaries (PBH Australia Holding Company Pty Limited and Care Pharmaceuticals Pty Limited) signed a Sale and Purchase Deed to acquire all shares of LaCorium Health Australia Pty Limited, Stantail Trading Pty Limited, Stantail International Pty Limited, Brands Worldwide Holdings I.P. Pty Limited, and Laderma Holdings Pty Limited for approximately $150 million in cash (subject to adjustments). The Company expects the transaction to close in the second quarter of fiscal 2027, subject to customary closing conditions.
• On May 13, 2026, Prestige filed an 8‑K disclosing its financial results for the fiscal quarter and year ended March 31, 2026 and began using an investor presentation related to those results (press release and slides furnished as Exhibits 99.1 and 99.2).

Key Details

• Purchase price: approximately $150 million in cash, subject to adjustments (including indebtedness adjustments set out in the agreement).
• Target businesses: five Australian companies described as a leader in Australian therapeutic skin care for treating individual skin ailments.
• Timing & conditions: expected close in Q2 fiscal 2027, subject to satisfaction/waiver of customary conditions; either party may terminate under specified breaches prior to Oct 1, 2026.
• Risk allocation: the purchaser obtained warranty and indemnity insurance that is its sole recourse for seller breaches of reps/warranties (except fraud); mutual indemnities and customary reps, warranties and limitations apply.

Why It Matters

• The deal is a material acquisition expanding Prestige’s presence in Australian therapeutic skin‑care, potentially adding new brands and revenue streams once closed.
• The $150M cash consideration and closing conditions are material to investors assessing Prestige’s capital deployment and near‑term financing needs; warranty and indemnity insurance limits the company’s remedy exposure for seller breaches.
• Investors should review the May 13, 2026 earnings press release and investor presentation for the company’s reported financial results and any commentary on the transaction’s impact.